Clinical Trial

Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2024 (before its estimated November 25, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are: * Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-12; most recent amendment 2024-08-09.
Trial Details
NCT Number NCT06168214
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions the Eradication Rates of Helicobacter Pylori
Enrollment 1,404 participants
Start Date 2023-09-04
Primary Completion 2024-11-25 (estimated)
Study Completion 2024-12-25 (estimated)
Updated on ClinicalTrials.gov 2024-08-13